Opexa Therapeutics (NASDAQ: ACER) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Opexa Therapeutics to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
This table compares Opexa Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Opexa Therapeutics Competitors||-5,229.27%||-213.46%||-38.10%|
This table compares Opexa Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Opexa Therapeutics||$2.90 million||-$7.97 million||-2.41|
|Opexa Therapeutics Competitors||$284.49 million||$34.10 million||64.09|
Opexa Therapeutics’ peers have higher revenue and earnings than Opexa Therapeutics. Opexa Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Opexa Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, Opexa Therapeutics’ peers have a beta of 5.94, indicating that their average stock price is 494% more volatile than the S&P 500.
This is a breakdown of current ratings for Opexa Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Opexa Therapeutics Competitors||892||3286||11782||235||2.70|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.64%. Given Opexa Therapeutics’ peers higher probable upside, analysts clearly believe Opexa Therapeutics has less favorable growth aspects than its peers.
Insider & Institutional Ownership
0.0% of Opexa Therapeutics shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 6.9% of Opexa Therapeutics shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Opexa Therapeutics peers beat Opexa Therapeutics on 8 of the 12 factors compared.
About Opexa Therapeutics
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.